Monopar Therapeutics Inc. (MNPR) Stock Score, Valuation & Financial Research

Monopar Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for MNPR

Monopar Therapeutics Inc. does not currently have a complete Wall Street Score. The stored market price is USD 79.38. These figures are a research snapshot, not a buy or sell recommendation.

What Monopar Therapeutics Inc. does

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Monopar Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and other financing activities to fund the research, development, and clinical testing of proprietary therapeutic candidates for unmet medical needs.

Products and services

  • The company is developing a pipeline of therapeutic candidates, primarily ALXN1840 for the treatment of Wilson disease and MNPR-101, a monoclonal antibody for cancer treatment.

Suppliers, materials and equipment

  • Contract Research Organizations and Contract Manufacturing Organizations — The company relies on third-party contract research organizations and contract manufacturing organizations for clinical trial management and drug supply; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Alexion Pharmaceuticals — Alexion transferred the sponsorship of the investigational new drug application for ALXN1840 to Monopar in 2025. Source

Business strengths to evaluate

  • Clinical-stage pipeline with orphan drug designation potential Source

Business risks and research considerations

  • History of operating losses and dependence on future financing Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

MNPR financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 79.38
Market capitalization:
531.77M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -17.84M
Free cash flow:
USD -12.2M
Cash:
USD 52.76M
Total debt:
USD 107.83K
EPS:
USD -2.34

What stands out

  • Free cash flow is USD -12.2M, negative for the stored period.
  • The balance sheet shows USD 52.76M of cash versus USD 107.83K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 52.65M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for MNPR

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can MNPR fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is MNPR likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for MNPR to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of MNPR's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-05.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research MNPR

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.